Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCENDANCE trial in newly diagnosed chronic phase chronic myeloid leukemia
ACTRN12623001338651Phase 2Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of asciminib and dasatinib in chronic myelogenous leukemia (CML) (3 arms), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoints: Early Molecular Response (EMR) and Molecular Response 4 (MR4). Started Oct 2024; status: completed.
02
Drugs
asciminibdasatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ACTRN12623001338651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001338651.